1 | tslim x2 insulin pump | | | | | | | 6 | 0.35% |
2 | technology is intended for | | | | | | | 4 | 0.23% |
3 | is indicated for use | | | | | | | 3 | 0.17% |
4 | is intended for single | | | | | | | 3 | 0.17% |
5 | the pump is indicated | | | | | | | 3 | 0.17% |
6 | the pump is intended | | | | | | | 3 | 0.17% |
7 | 6 years of age | | | | | | | 3 | 0.17% |
8 | pump is intended for | | | | | | | 3 | 0.17% |
9 | controliq technology is intended | | | | | | | 3 | 0.17% |
10 | insulin the pump is | | | | | | | 3 | 0.17% |
11 | is able to reliably | | | | | | | 2 | 0.12% |
12 | communicate with compatible digitally | | | | | | | 2 | 0.12% |
13 | tandem diabetes care has | | | | | | | 2 | 0.12% |
14 | pump is able to | | | | | | | 2 | 0.12% |
15 | the pump is able | | | | | | | 2 | 0.12% |
16 | your insulin pump to | | | | | | | 2 | 0.12% |
17 | for use in individuals | | | | | | | 2 | 0.12% |
18 | the tslim x2 insulin | | | | | | | 2 | 0.12% |
19 | requiring insulin the pump | | | | | | | 2 | 0.12% |
20 | dosing software to receive | | | | | | | 2 | 0.12% |
21 | the management of diabetes | | | | | | | 2 | 0.12% |
22 | for the management of | | | | | | | 2 | 0.12% |
23 | rates for the management | | | | | | | 2 | 0.12% |
24 | variable rates for the | | | | | | | 2 | 0.12% |
25 | and variable rates for | | | | | | | 2 | 0.12% |
26 | set and variable rates | | | | | | | 2 | 0.12% |
27 | the subcutaneous delivery of | | | | | | | 2 | 0.12% |
28 | automated insulin dosing software | | | | | | | 2 | 0.12% |
29 | commands from these devices | | | | | | | 2 | 0.12% |
30 | software to receive execute | | | | | | | 2 | 0.12% |
31 | in individuals 6 years | | | | | | | 2 | 0.12% |
32 | x2 insulin pump with | | | | | | | 2 | 0.12% |
33 | indicated for use with | | | | | | | 2 | 0.12% |
34 | for use with novolog | | | | | | | 2 | 0.12% |
35 | use with novolog or | | | | | | | 2 | 0.12% |
36 | with novolog or humalog | | | | | | | 2 | 0.12% |
37 | automated insulin delivery system | | | | | | | 2 | 0.12% |
38 | tandem automated insulin delivery | | | | | | | 2 | 0.12% |
39 | individuals 6 years of | | | | | | | 2 | 0.12% |
40 | use in individuals 6 | | | | | | | 2 | 0.12% |